甲状腺功能亢进(简称甲亢)是甲状腺分泌过多甲状腺素或血循环中甲状腺激素水平增高的一组常见内分泌疾病.同时也是内科疾病中与精神活动关系较为密切的一组疾病.临床以弥漫性毒性甲状腺肿(graves disease,GD)最常见,患者除有甲状腺肿大和高代谢症候群、突眼等症状外,常表现出情感不稳,易激惹、躁狂或抑郁等症状.

OBJECTIVE: To review the correlation between type 2 diabetes mellitus and depression and make clear further the correlation between them. DATA SOURCES: We searched for the related literatures in the Medline database and the Ovid database published from February 2000 to September 2005 with the of "depression ,Type 2 Diabetes Mellitus,depression & Type 2 Diabetes Mellitus" in English.STUDY SELECTION: The articles were selected primarily, and those accorded with the criteria were included and the full-texts of them were looked up. Inclusive criteria were: original works on epidemiology of type 2 diabetes mellitus and depression; ②original works on biological correlation of type 2 diabetes mellitus and depression; ③the influence of depression on type 2 diabetes mellitus; ④therapeutic research of type 2 diabetes mellitus patients with depression. Exclusive criterion: Literatures with repetitive researches were excluded.DATA EXTRACTION: Twenty-three articles were retrieved from Medline and thirty-three from Ovid. Fifteen articles were selected as references.DATA SYNTHESIS: There were a variety of dangerous factors that might cause depression in the patients with type 2 diabetes mellitus such as hyperglycemia, low socioeconomic status, low educational level, female, less than 65 years, abnormal personality, obesity and so on. The biological correlation between type 2 diabetes mellitus and depression involved several aspects such as neuroendocrine, neuro-biochemistry, neruo-immune and so on. Patients with type 2 diabetes mellitus, with depression as a kind of complications, had decreased living quality, damaged physiological function and bad prognosis. For the patients with type 2 diabetes mellitus and depression, psychological therapy and anti-depression therapy played a positive and important role.CONCLUSION: The correlation between depression and type 2 diabetes mellitus involves various aspects. It is necessary to study their correlation and mechanism of epidemiology, neuroendocrine, neuro-chemistry and so on.

AIM To evaluate the efficacy of reboxetine in the treatment of anxiety in depressive patients.METHODS To compare with fluoxetine,the randomized,double-blind,double-dummy clinical trial was designed for this study.There were 137 depressive patients were enrolled(Hamilton Rating Scale for Depression(HAMD)≥18 and Hamilton Anxiety Scale(HAMA)≥14)and 132 patients completed the whole therapy,64 patients in reboxetine group(study group),68 in fluoxetine group(control group).Patients in study group took reboxetine 8 mg·d~(-1),and fluoxetine 20 mg·d~(-1) in control group.The treatment duration was 6 wk.HAMA and HAMD were used to evaluate the symptoms in patients at baseline and wk 1,2,4 and 6.RESULTS The HAMA score reduction in study group was(16.25±6.16)and((14.29±)7.45)in controll group after 6 wk(P=0.028 9).There was significant difference between 2 groups.CONCLUSION Reboxetine is a safe and effective antidepressant in the treatment of anxiety in depressive patients.

AIM: To evaluate efficacy and safety of reboxetine in treating depression. METHODS: In this randomized, double-blind, double-mimicry, fluoxetine parallel controlled, fixed dosage, multicenter study, the study group was treated with reboxetine capsule 8 (mg·d~(-1)) and the control group with fluoxetine tablet 20 mg·d~(-1). Hamilton Rating Scale for Depression (17-(item) HAMD) total reduction value was taken as the primary efficacy score while Clinical Global Impression (CGI) and Hamilton Rating Scale for Anxiety (HAMA) were used as secondary score, items including the TESS, lab examination and vital signs for assessment of safety. RESULTS: Among 222 patients with depression (ITT), 109 subjects treated with reboxetine (study group) and other 113 patients with fluoxetine (control group). Per Protocol (PP) 213 patients included reboxetine group (104) and fluoxetine group (109). After 6 wk treatment, a statistically significant greater reduction in HAMD total score was found for both reboxetine group (16±7) and fluoxetine group (16±7) showing statistical significsnce with their baseline (P(0.01)), however, there was no significant difference between two active treatment groups (P(0.05)). There were great proportion of patients treated with either reboxetine or fluoxetine showing positive response rates (≥50 % reduction in HAMD, (81.7 %) versus 77.9 %) and remission rates ((HAMD≤)8 points, 62.4 % versus 58.4 %), nevertheless still no significant difference between two groups was shown (both P(0.05)). Similar findings were recorded in CGI and HAMA. Safety assessment showed there was no statistically significant deference between the symptoms and incidence of adverse reaction. CONCLUSION: Reboxetine is an effective and safe antidepressant.

近来,我总是觉得心里很烦,常常睡不着觉,还出现心悸手抖,我已经去医院看了很多次,医生说是焦虑症,给我开了不少抗焦虑的药.但是,这些药对我除了大量的副反应,根本就没有任何作用.现在我的症状一点儿也没有得到改善,真不知该怎么办,望给予指点.

目的探讨在校大学生人格特征的动态变化.方法用卡特尔16种人格因素测试量表(16PF)、艾森克成人个性问卷(EPQ)对一个年级的学生114名每年进行一次测评,从大一到大四连续4年.结果发现16PF量表中B、E、F、H、L、O、Q1、Q2、Q3因子分,EPQ量表中N、E和L量表在4年中存在显著性差异.经SNK两两比较,在第4年观察时,聪慧性、恃强性、兴奋性、敢为性、实验性、自律性等人格特征进一步完善,但专业成就因素及新环境中成长因素有所下降.结论大学教育必须重视人格及人际沟通能力的培养,以促进身心健康发展.

目的探讨不同院校在校大学生人格特征的差异与心理健康因素的关系.方法用卡特尔16种人格因素测试量表(16PF),艾森克成人个性问卷(EPQ)对3所大学的3年级学生各97名同期进行测评.结果发现16PF量表中E、N、O因子分,EPQ量表中N和L量表3所院校学生间存在显著性差异.经SNK两两比较法比较,发现后勤工程学院学生具忧虑性人格特征,心理健康因素也低于重庆医科大学和重庆邮电学院学生.邮电学院学生具低恃强性人格特征.重庆医科大学和重庆邮电学院的男生均比女生聪慧,更具创造能力和新环境中成长能力.结论部分院校学生间个性的差异,及对心理健康等因素的影响,提醒高校教育工作者应加强大学生个性的培养.

目的:为进一步探索老年人抑郁的临床特征和更加安全有效的治疗方法;方法:选择了30名60岁以上有明显抑郁症状的老年人对其临床特征进行分析,用新型抗抑郁剂SSRI类的百忧解结合心理治疗的方法进行治疗,并与20名采用阿米替林治疗的老年病人进行对照.结果:老年人抑郁症状主要表现为持续的心境恶劣,症状通常很模糊,情绪低落,常被隐藏起来,焦虑经常是主要症状;结论:百忧解结合适当的心理治疗对老年人由各种因素引起的抑郁症状是很好的治疗方法.

近年来,中学生的行为问题受到了越来越多的关注(3),随着我国独生子女的增多,中学教育显得尤为重要,特别是高中学生,面临升学、择业的重要时刻.通过对人格特征的探讨,以便了解他们人格的倾向性,对我国中学教育的研究具有较大的参考价值.